SynthesisRMD open2026
Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis.
Synthesis in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reprogramming macrophage polarization via CD44-targeted and ROS-responsive apabetalone-loaded micelles for rheumatoid arthritis treatment.International journal of pharmaceutics: X · 2026Article
- Bone Health in Rheumatoid Arthritis: An Update.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of 2 years of low-dose glucocorticoid (GC) treatment on bone mineral density and fracture risk in patients with rheumatoid arthritis (RA).
methodsWe performed a protocolised (dx.doi.org/10.17504/protocols.io.6qpvr3ombvmk/v1) systematic literature review and individual participant data meta-analysis of randomised trials in early and established RA, which compared GCs at ≤7.5 mg prednisone equivalent/day with placebo or standard of care. All patients could receive background treatment with disease-modifying antirheumatic drugs. Changes in lumbar spine and femoral bone density and participants with ≥1 clinical fracture over 2 years in intention-to-treat analyses were coprimary endpoints. Main analyses were based on one-stage models; I² was estimated from two-stage models. Missing data were handled using multiple imputation. Several sensitivity analyses assessed the robustness of our results.
resultsOut of 2336 articles, five out of six identified trials provided individual participant data (1112 participants). Greater bone loss was observed at the lumbar spine in the GC compared with the control group (-0.021 g/cm²; 95% CI -0.037 to -0.005; p=0.034; I²=31%) but not at the femur (0.004 g/cm²; 95% CI -0.008 to 0.016; p=0.47; I²=0%). Subgroup analyses did not reveal groups particularly susceptible to GC-induced bone loss at the lumbar spine. 35 participants experienced ≥1 fracture; fracture risk was comparable in both groups. Sensitivity analyses yielded consistent results.
conclusionLow-dose GCs, used for 2 years to treat RA, lead to bone loss at the lumbar spine but not at the femur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.